Effect of pregnancy-specific β1-glycoprotein on myeloid-derived suppressor cell differentiation

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous cell population that primarily suppress T lymphocytes in healthy pregnancies and pathologies. MDSCs are one of the key regulators of immune responses. Finding ways to control them is important for the treatment of cancer, autoimmune diseases, miscarriage, and post-transplant complications. The mechanisms of immune suppression by MDSC are: expression of CD73, ADAM17, PD -L1, production of Arg 1, iNOS, IDO, IL -10 and TGF-b1.

Pregnancy-specific b1-glycoprotein (PSG) has modulatory effects on dendritic cells and macrophages that mediate the shift of T cell phenotypes toward Th2 and Treg. We have previously shown that native PSG suppresses Th17 differentiation and cytokine production, stimulates the production of IDO by monocytes and the differentiation of Tregs.

Considering the immunomodulatory properties of PSG and the key role of MDSCs in pathologies, the aim of our work was to investigate the effect of native and recombinant PSG on the differentiation of MDSCs in vitro.

MDSCs were differentiated from CD11b⁺ peripheral blood cells. Cells were cultured for 7 days and received stepwise GM-CSF, IL-1b, and LPS. Native (n) (1; 10 and 100 mg/mL) and recombinant (r) (1 and 10 mg/mL) PSG were introduced into the cultures three days before the end of incubation. Flow cytometry was used to determine the percentage of MDSC among the cells in culture and the percentage of M-, PMN-, and e-MDSC among the total number of MDSCs.

It was found that rPSG (1 mg/mL) increased the percentage of MDSCs in culture. Both nPSG (1 and 10 mg/mL) and rPSG (10 mg/mL) increased the proportion of M-MDSC, whereas rPSG (10 mg/mL) decreased the number of PMN-MDSC.

Thus, the cytokine background in CD11b⁺ cell cultures favored the differentiation of predominantly M-MDSC, similar to the tumor microenvironment, whereas native and recombinant PSG enhanced this effect. Thus, nPSG and rPSG are able to modulate the differentiation of MDSCs by increasing their number, mainly due to the monocytic subpopulation. This fact opens perspectives for new research on targeted manipulation of MDSCs.

1. Atretkhany K.-S.R., Drutskaya M.S. Myeloid suppressor cells and pro-inflammatory cytokines as targets for cancer therapy. Biochemistry, 2016, Vol. 81, no. 12, pp. 1520-1529.

2. Blois S.M., Sulkowski G., Tirado-González I., Warren J., Freitag N., Klapp B.F., Rifkin D., Fuss I., Strober W., Dveksler G.S. Pregnancy-specific glycoprotein 1 (PSG1) activates TGF-β and prevents dextran sodium sulfate (DSS)-induced colitis in mice. Mucosal Immunol., 2014, Vol. 7, no. 2, pp.348-358.

3. Bohn H., Johannsen R., Kraus W. New placental protein (PP15) with immunosuppressive properties. Arch. Gynaecol., 1980, no.230, pp.167-172.

4. Gabrilovich D.I. Myeloid-derived suppressor cells. Cancer Immunol. Res., 2017, Vol. 5, no. 1, pp. 3-8.

5. Hertz J. B., Schultz-Larsen P. Human placental lactogen, pregnancy-specific beta-1-glycoprotein and alphafetoprotein in serum in threatened abortion. Int. J. Gynaecol .Obstet., 1983, no. 21, pp. 111-117.

6. Jayaraman P., Parikh F., Newton J.M., Hanoteau A., Rivas C., Krupar R., Rajapakshe K., Pathak R., Kanthaswamy K., MacLaren C., Huang S., Coarfa C., Spanos C., Edwards D.P., Parihar R., Sikora A.G. TGF-β1 programmed myeloid-derived suppressor cells (MDSC) acquire immune-stimulating and tumor killing activity capable of rejecting established tumors in combination with radiotherapy. Oncoimmunology, 2018, Vol. 7, no. 10, e1490853. doi: 10.1080/2162402X.2018.1490853.

7. Mojsilovic S., Mojsilovic S.S., Bjelica S., Santibanez J.F. Transforming growth factor-beta1 and myeloidderived suppressor cells: A cancerous partnership. Dev. Dyn., 2022, Vol. 251, no. 1, pp. 105-124.

8. Ostrand-Rosenberg S., Sinha P., Figley C., Long R., Park D., Carter D., Clements V.K. Frontline Science: Myeloid-derived suppressor cells (MDSCs) facilitate maternal-fetal tolerance in mice. J. Leukoc. Biol., 2017, Vol. 101, no. 5, pp. 1091-1101.

9. Pang B., Hu C., Li H., Nie X., Wang K., Zhou C., Yi H. Myeloid-derived suppressor cells: Escorts at the maternal-fetal interface. Front. Immunol., 2023, Vol. 14, e1080391. doi: 10.3389/fimmu.2023.1080391.

10. Rayev M.B. Method for isolation and purification of trophoblastic β1-glycoprotein. RF Patent. 2009; 2367449 (Bull): 26.

11. Tatarinov Y.S., Masyukevich V.N. Immunochemical identification of new β-1 globulin in the blood serum of pregnant women. Bull. Eksp. Biol. Med. USSR, 1970, no. 69, pp. 66-68. (In Russ.)

12. Temur M., Serpim G., Tuzluoğlu S., Taşgöz F.N., Şahin E., Üstünyurt E. Comparison of serum human pregnancy-specific beta-1-glycoprotein 1 levels in pregnant women with or without preeclampsia. J. Obstet. Gynaecol., 2020, Vol. 8, pp. 1074-1078.

13. Timganova V.P., Zamorina S.A., Litvinova L.S., Todosenko N.M., Bochkova M.S., Khramtsov P.V., Rayev M.B. The effects of human pregnancy-specific β1-glycoprotein preparation on Th17 polarization of CD4+ cells and their cytokine profile. BMC Immunol., 2020, Vol. 21, no. 1, e56. doi: 10.1186/s12865-020-00385-6.

14. Veglia F., Sanseviero E., Gabrilovich D.I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol., 2021, no. 21, pp. 485-498.

15. Youn J.I., Gabrilovich D.I. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur. J. Immunol., 2010, Vol. 40, no. 11, pp. 2969-2975.